Biotechnology - Rare diseases, Pricing


Current filters:

Rare diseasesPricing

Popular Filters

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri


US biotech firm Cell Therapeutics has concluded an agreement with the Germany’s National Association…

BiotechnologyCell TherapeuticsOncologyPixuvriPricingRare diseases

UK's NICE calls for more data to consider Roche drug for a type of vasculitis


UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM


US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData


Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

UK's NICE to takeover role of assessing high-cost rare disease drugs


In the UK, the role of assessing very high cost drugs for people who suffer with rare conditions, under…

BiotechnologyEuropePharmaceuticalPricingRare diseasesRegulation

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra


The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Back to top